Allergan “Cedar” 150998-005

Complete Study

A Phase III, Multi-Center, randomized, double-masked, parallel group to assess the Safety and Efficacy of Abicipar compared to Ranibizumab in patients with Neovascular Age-Related Macular Degeneration.

Duration: 104 weeks

This entry was posted in Uncategorized. Bookmark the permalink.